Adoptive Cell Therapy Market Status (2016-2020) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2021-2027
Report Description
The global Adoptive Cell Therapy market size is estimated at USD 11,440.7 million in 2020, expanding at a CAGR of 30.4% from 2021-to 2027 to reach 21,440.7 Million USD in 2027.
Market Dynamics
Adoptive cell therapy (ACT) is a type of immunotherapy in which a patient is given T cells (a type of immune cell) to help the body fight diseases such as cancer. Chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor-infiltrating lymphocytes (TILs), and natural killer (NK) cells are all examples of adoptive cell therapy. Adoptive cell therapy involves the use of large numbers of immune cells grown in the lab before being administered to the body to fight cancer. Immune cells that naturally recognize melanoma are sometimes used, while other times they are modified to recognize and kill melanoma cells. T-cell transfer therapy and cellular immunotherapy are other terms for adoptive cell therapy.
Regional Insights
Among regions, North America is estimated to hold a dominant position in the global adoptive cell therapy market in 2022 owing to key players in the market focusing on product approvals for adoptive cell therapy. For example, NantKwest Inc., a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the company's immune system using natural killer (NK) cells to treat cancer, infectious diseases, and other diseases, announced in June 2021 that the company's t-haNK is a human-derived, allogeneic, natural killer cell line engineered to express a chimeric antigen receptor (CAR) targeting PD-L1, whose origins.
Due to key players in the market focusing on growth strategies such as acquisition, Asia Pacific is expected to exhibit a higher CAGR in the global adoptive cell therapy market over the forecast period. For example, Laurus Labs, an India-based pharma and biotech company, announced in November 2021 that it had signed an agreement to invest in Immunoadoptive Cell Therapy (ImmunoACT), an IIT-Bombay incubated company developing an indigenous CAR T-cell therapy for treating specific types of blood cancers. For a cash consideration of approximately 46 crores (US $ 460 million), Laurus Labs will acquire a 26.62 percent (fully diluted) stake in ImmunoACT.
Segment Insights
The Adoptive Cell Therapy market is fragmented into type, application, and end-user segments. Based on the type, the CAR-T is anticipated to dominate the market. Based on application, lymphoma is anticipated to have a higher growth rate in the coming years. By end-user, the hospital segment is expected to hold the majority of the market share.
Competitive Insights
Key players in the global adoptive cell therapy market are focusing on growth strategies such as product launch, collaboration, and fundraising, which are expected to drive market growth over the forecast period. Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company, announced in January 2021 that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma.
The report begins with an overview of the Industry Chain structure, and describes the industry environment, then analyses the market size and forecast of Adoptive Cell Therapy by type, application, end-user, and region. In addition, this report introduces the market competition situation among the vendors, and the company profile, besides, market price analysis, and value chain features are covered in this report.
Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):
- Novartis AG
- Gilead Sciences, Inc
- Castle Creek Biosciences, Inc
- Lineage Cell Therapeutics, Inc.
- Transgene SA
- Cellectis
- ImmunityBio, Inc
- Sorrento Therapeutics
- bluebird bio, Inc
- Arcellx
- Sana Biotechnology, Inc
- Biodesix, Inc
- Laurus Labs
Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):
- CAR-T
- TCR-T
- NK
- TIL
Application Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):
- Lymphoma
- Leukemia
- Others
End-User Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):
- Hospitals
- Cancer Treatment Centres
- Others
Region Coverage (Regional Consumption, Demand & Forecast by Countries, etc.):
- North America (U.S., and Canada)
- Europe (Germany, U.K., France, Italy, Spain, etc.)
- Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
- South America (Brazil, Mexico, Argentina, etc.)
- Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa, etc.)
Table Of Content
1. Adoptive Cell Therapy Market Overview
1.1. Product Overview and Scope of Adoptive Cell Therapy
1.2. Global Market Growth Prospects and Revenue Estimates
1.3. Global Adoptive Cell Therapy Market Size Growth Rate Analysis by Type 2020 VS 2027
1.3.1. CAR-T
1.3.2. TCR-T
1.3.3. NK
1.3.4. TIL
1.4. Global Adoptive Cell Therapy Comparison by Application: 2020 VS 2027
1.4.1. Lymphoma
1.4.2. Leukemia
1.4.3. Others
1.5. Global Adoptive Cell Therapy Comparison by End User: 2020 VS 2027
1.5.1. Hospitals
1.5.2. Cancer Treatment Centers
1.6. Global Adoptive Cell Therapy Market Size Estimates and Forecasts by Region: 2020 VS 2027
1.6.1. North America Adoptive Cell Therapy Estimates
1.6.2. Europe Adoptive Cell Therapy Estimates
1.6.3. Asia Pacific Adoptive Cell Therapy Estimates
1.6.4. South America Adoptive Cell Therapy Estimates
1.6.5. Middle East & Africa Adoptive Cell Therapy Estimates
2. Market Competition by Manufacturers
2.1. Global Adoptive Cell Therapy Revenue Market Share by Manufacturers (2020)
2.2. Adoptive Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.3. Global Adoptive Cell Therapy Average Price by Manufacturers (2020-2027)
2.4. Manufacturers Adoptive Cell Therapy Production Sites, Area Served, Product Types
2.5. Adoptive Cell Therapy Market Competitive Situation and Trends
2.5.1. Adoptive Cell Therapy Market Concentration Rate
2.5.2. Mergers & Acquisitions, Expansion
3. Global Adoptive Cell Therapy Consumption by Region (2020-2027)
3.1. Global Adoptive Cell Therapy Consumption by Region
3.2. Global Adoptive Cell Therapy Consumption Market Share by Region
3.2.1. North America
3.2.2. North America Adoptive Cell Therapy Consumption Growth Rate (2020-2027)
3.2.3. North America Adoptive Cell Therapy Consumption, Price and Gross Margin (2020-2027)
3.2.4. North America Adoptive Cell Therapy Consumption by Country
3.2.4.1. U.S.
3.2.4.2. Canada
3.2.5. Europe
3.2.6. Europe Adoptive Cell Therapy Consumption Growth Rate (2020-2027)
3.2.7. Europe Adoptive Cell Therapy Consumption, Price and Gross Margin (2020-2027)
3.2.8. Europe Adoptive Cell Therapy Consumption by Country
3.2.8.1. Germany
3.2.8.2. U.K.
3.2.8.3. France
3.2.8.4. Italy
3.2.8.5. Spain
3.2.9. Asia Pacific
3.2.10. Asia Pacific Adoptive Cell Therapy Consumption Growth Rate (2020-2027)
3.2.11. Asia Pacific Adoptive Cell Therapy Consumption, Price and Gross Margin (2020-2027)
3.2.12. Asia Pacific Adoptive Cell Therapy Consumption by Country
3.2.12.1. China
3.2.12.2. India
3.2.12.3. Japan
3.2.12.4. Indonesia
3.2.12.5. Malaysia
3.2.12.6. Australia
3.2.12.7. South Korea
3.2.13. South America
3.2.14. South America Adoptive Cell Therapy Consumption Growth Rate (2020-2027)
3.2.15. South America Adoptive Cell Therapy Consumption, Price and Gross Margin (2020-2027)
3.2.16. South America Adoptive Cell Therapy Consumption by Country
3.2.16.1. Brazil
3.2.16.2. Mexico
3.2.16.3. Argentina
3.2.17. Middle East and Africa
3.2.18. Middle East and Africa Adoptive Cell Therapy Consumption Growth Rate (2020-2027)
3.2.19. Middle East and Africa Adoptive Cell Therapy Consumption, Price and Gross Margin (2020-2027)
3.2.20. Middle East and Africa Adoptive Cell Therapy Consumption by Country
3.2.20.1. Saudi Arabia
3.2.20.2. Kuwait
3.2.20.3. UAE
3.2.20.4. South Africa
4. Global Adoptive Cell Therapy Consumption by Type (2020-2027)
4.1. Global Adoptive Cell Therapy Price by Type (2020-2027)
4.2. Global Adoptive Cell Therapy Revenue Market Share by Type (2020-2027)
4.2.1. CAR-T
4.2.2. TCR-T
4.2.3. NK
4.2.4. TIL
5. Global Adoptive Cell Therapy by Application (2020-2027)
5.1. Global Adoptive Cell Therapy Price by Application (2020-2027)
5.2. Global Adoptive Cell Therapy Revenue Market Share by Application (2020-2027)
5.2.1. Lymphoma
5.2.2. Leukaemia
5.2.3. Others
6. Global Adoptive Cell Therapy Consumption by End User (2020-2027)
6.1. Global Adoptive Cell Therapy Price by End User (2020-2027)
6.2. Global Adoptive Cell Therapy Revenue Market Share by End User (2020-2027)
6.2.1. Hospitals
6.2.2. Cancer Treatment Centers
7. Key Companies Profiled
7.1.1. BASF SE
7.1.2. BASF SE Adoptive Cell Therapy Corporation Information
7.1.3. BASF SE Adoptive Cell Therapy Product Portfolio
7.1.4. BASF SE Adoptive Cell Therapy Consumption, Price and Gross Margin (2020-2027)
7.1.5. BASF SE Main Business and Markets Served
7.1.6. BASF SE Recent Developments/Updates
7.2. Gilead Sciences, Inc
7.3. Castle Creek Biosciences, Inc
7.4. Lineage Cell Therapeutics, Inc.
7.5. Transgene SA
7.6. Cellectis
7.7. ImmunityBio,
7.8. Inc Sorrento Therapeutics
7.9. bluebird bio, Inc
7.10. rento Therapeutics
7.11. Arcellx
7.12. Sana Biotechnology, Inc
7.13. Biodesix, Inc
7.14. Laurus Labs
8. Marketing Channel, Distributors and Customers
8.1. Marketing Channel
8.2. Adoptive Cell Therapy Distributors List
8.3. Adoptive Cell Therapy Customers
9. Market Dynamics
9.1. Adoptive Cell Therapy Industry Trends
9.2. Adoptive Cell Therapy Growth Drivers
9.3. Adoptive Cell Therapy Market Challenges
9.4. Adoptive Cell Therapy Market Restraints
10. Global Adoptive Cell Therapy Consumption and Demand Forecast, by Region (2022-2027)
10.1. Global Forecasted Demand Analysis of Adoptive Cell Therapy, by Regions and Country
10.1.1. North America Forecasted Consumption of Adoptive Cell Therapy by Country
10.1.2. Europe Market Forecasted Consumption of Adoptive Cell Therapy by Country
10.1.3. Asia Pacific Market Forecasted Consumption of Adoptive Cell Therapy by Region
10.1.4. Latin America Forecasted Consumption of Adoptive Cell Therapy by Country
10.1.5. Middle East and Africa Forecasted Consumption of Adoptive Cell Therapy by Country
11. Research Finding and Conclusion
12. Methodology and Data Source
12.1. Methodology/Research Approach
12.1.1. Research Programs/Type
12.1.2. Market Size Estimation
12.1.3. Market Breakdown and Data Triangulation
12.2. Data Source
12.2.1. Secondary Sources
12.2.2. Primary Sources
12.3. Author List
12.4. Disclaimer
Research Methodology
Our research studies are primarily performed in five phases which include Secondary Research, Primary Research, Subject Matter Expert Advice, Quality Check, and Final Review. The process opted for conducting thorough research to make authentic business reports is briefly described below-
Secondary Research-
- Based on the understanding of requirements, we conducted secondary research to identify the Segment specifications, qualitative and quantitative data along with the factors responsible for the growth of the market.
- The secondary sources referred for the study include press releases, company annual reports, and research papers related to the industry.
- Various sources such as industry magazines, trade journals, government websites, and associations were also reviewed for gathering precise analysis on opportunities for business expansions in the market.
- Moreover, quantitative as well as qualitative data were also extracted from paid databases, which included Reuters, Factiva, Bloomberg, One Source, and Hoovers, which proved to be useful for in-depth technical study of the market.
Primary Research-
- The research carried out during the desk research was verified by primary interviews. Primary research was scheduled with a number of industry experts for conducting telephonic interviews, and also our team send questionnaires through their official emails.
- The secondary data collected was then verified by various industry participants which included Segment managers, marketing managers, VPs, CEOs, purchasing managers, subject matter experts.
- An interview with the mentioned participants aids invalidation of our research findings regarding the Segment.
- It helps in the provision of first-hand data on factors such as market size, growth, regional trends, market trends, and competition in the industry. This approach makes our findings precise in order to help our clients in strategic decision-making processes.
Subject Matter Advice-
- The secondary and primary research key findings were then validated by the in-house subject matter experts having extensive experience in the market research industry.
- Specific requirements of the clients were reviewed by the experts to check for completion of the market study. Experts help in channelizing the representation skills of the analyst in terms of providing data that can be easily understood by our customers.
Quality Check-
- The analysis done by the research team was further reviewed to check for data accuracy provided to suit the clients’ specific requirements.
- This revision was done in various phases to check the data authenticity and to remove negligible errors in the final compilation.
Final Review-
- After the quality check, a final review of the report was done to look after the presentation, formatting, and to recheck if all the requirements of the clients were addressed. The next phase remains dispatch of the report to the client.
Enquire Before Purchase
Frequently Asked Questions
Why Choose Market Research Strategy?
We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports
We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround
Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.
We abide by the information security policy and adheres to keep your private and business information confidential and secure.